摘要
目的探讨托伐普坦治疗急性失代偿期心衰(acute decompensated heart failure,ADHF)伴低血钠症患者的近期疗效。方法 53例ADHF患者按随机数字表法分为对照组(23例)和研究组(30例)。对照组给予常规药物进行治疗,研究组在对照组的基础上加用托伐普坦。每天记录患者的体质量、血压及尿量,并实时观察有无不良事件发生。7 d后比较2组患者的血钠浓度、尿量、LVEF、NT-pro BNP及心衰体征改善情况。结果治疗7 d后,研究组血钠浓度、LVEF均较对照组明显提升(P<0.05);研究组尿量、NT-pro BNP均较对照组明显改善(P<0.05)。研究组心衰症状改善的总有效率为93.3%,明显高于对照组(69.6%,P<0.05)。结论托伐普坦可以显著提高ADHF伴低血钠症患者的血钠水平,增加尿量,降低NT-pro BNP,改善患者的心衰体征。
Objective To investigate the short-term effect of tolvaptan in treatment of acute decompensated heart failure（ ADHF） combined with low sodium blood sickness. Methods Fifty-three cases of ADHF combined with low sodium blood sickness patients were randomly divided into control group（ 23 cases） and study group（ 30 cases）. The control group were treated with normal medicine,while the treatment group were given tolvaptanon on the basis of control group. The patient＇s body quality,blood pressure,urine volume,and adverse events in real time were recorded. the serum sodium level,serum sodium level,LVEF,NT-pro BNP and heart failure symptoms after 7days＇ treatment were compared. Results The serum sodium level and LVEF of the study group were all significantly improved than that of the control group after 7days＇ treatment（ P〈0. 05）; the urine volume and NTpro BNP of the study group were all significantly improved than that of the control group（ P〈0. 05）. The total effective rate of the heart failure symptoms of the study group was 93. 3%,which was higher than that of the control group（ 69. 6%,P〈0. 05）. Conclusion The therapy of tolvaptan can significantly improve the serum sodium level,increase the urine volume and reduce the NT-pro BNP level for patients suffered with ADHF combined with low sodium blood sickness. And it can also improve the heart failure symptoms.
出处
《中国生化药物杂志》
CAS
2016年第3期49-51,共3页
Chinese Journal of Biochemical Pharmaceutics
关键词
托伐普坦
急性失代偿心衰
低血钠症
tolvaptan
acute decompensated heart failure
low sodium blood sickness
